PR/Comms, @noom. Formerly: @pagayaltd, @nbcnews, @qz, @FT. Sunglasses junkie, candy enthusiast, Rock Chalk. Views are my own. emily.passer@pagaya.com
NYC
Joined June 2009
- Tweets6.5K
- Following2.8K
- Followers2.1K
- Likes6.7K
Emily Passer retweeted
This week on The MM+M Podcast, @Noom CEO Geoff Cook talks “Weight Regain Doesn’t Care,” the impact of the broader Losing for Keeps effort, the role of celebs in GLP-1 marketing and what other examples of GLP-1 advertising have impressed him.
mmm-online.com/podcasts/noom…
Emily Passer retweeted
$HIMS
🚨 BREAKING: FDA PEPTIDES PANEL VOTES "YES" ON 6 OUT OF 7 PEPTIDES
1. BPC-157
2. KPV
3. TB-500
4. MOTS-C
5. EPITALON
6. SEMAX
THE ONE "NO" VOTE: EMIDELTIDE
Emily Passer retweeted
Excited to introduce Lose for Keeps — Noom's new campaign featuring Rebel Wilson, now launched across TV, streaming, social, and digital.
Medication can create an opening for change. Habits help make it last.
Watch the spots and read more here: lnkd.in/gXe5UwKW
Emily Passer retweeted
NOOM LAUNCHES FREE VERSION OF ITS GLP-1 COMPANION
- Available at no cost to anyone taking a GLP-1, regardless of provider (e.g., $HIMS and Ro)
- Preliminary Noom data show that Noom members had roughly 3x stronger weight maintenance after stopping GLP-1s vs control group
Emily Passer retweeted
Noom CEO @geoffcook is heading to the @ftlive x @endpts US Pharma & Biotech Summit on May 14, speaking on a panel tackling longevity medicine's biggest questions: what's driving innovation, where investment is going, and whether it's reaching the people who need it most.
Learn more: bit.ly/42Jw94A #FTPharma
Emily Passer retweeted
Honored to be named to @TIME's inaugural TIME100 Companies: Industry Leaders list 🙌
The future of health isn't a drug or an app — it's what happens when lasting behavior change meets cutting-edge clinical care.
That's what we're building. bit.ly/420Ed0F
Emily Passer retweeted
🎉 Exciting news! Our Mindful Art Break feature has been nominated for @TheWebbyAwards in the Apps, Software & Immersive - Health, Wellness & Fitness category - built on the belief that a moment of awe can be a moment of healing.
Voting is open now through Thursday, April 16 at 11:59pm PDT - cast your vote here: bit.ly/3NAwHpN
Emily Passer retweeted
$HIMS $LLY $NVO
🚨 BREAKING: Noom is acquiring a 503A pharmacy to prepare for the peptide boom
We sat down with @GeoffCook (Noom CEO) to discuss why vertical integration is so important, how large the peptide market is going to be, and the evolving dynamics between telehealth platforms and big pharma
A great episode with one of the best CEOs in the game - thanks again, Geoff!
00:00 - Why pharma needs DTC platforms
03:03 - Noom's 90% revenue growth
05:01 - Why Noom bought Tailor Made Compounding
07:29 - The case for vertical integration
08:56 - Compounded GLP-1s aren't going anywhere
16:48 - The Hims-Novo deal
19:08 - Noom's pitch to next-gen pharma
24:24 - Peptide market sizing
25:33 - Why GLP-1 users will buy peptides first
27:22 - Ten million potential peptide patients 👀
30:09 - When will legalization happen?
31:09 - Tracking the FDA green list
34:26 - Who wins when peptides go legal?
37:58 - Why Noom won't rush peptide launch
39:33 - Geoff's BPC-157 ski injury recovery
46:42 - Expanding at-home labs past 30 biomarkers
52:47 - Noom IPO coming?!
Not financial, legal, or medical advice
Emily Passer retweeted
🚨 Excited to announce that Noom CEO @geoffcook will be returning to the $HIMS House podcast next week
Emily Passer retweeted
💡 11 out of 12 people stop taking GLP-1s within a few years. GLP-1 therapy opens the door to change, but it doesn’t replace the need for sustained behavioral support.
That was the message from Noom CEO @geoffcook at the Stanford Consumer Health Summit.
Read the full story via @athletechnews 🔗 bit.ly/3PfiRt4
Emily Passer retweeted
We're honored to debut on @Newsweek's Most Trusted Brands 2026 list ✨
The article highlights how Noom continues to evolve - from habit science and GLP-1 support to biomarker testing and ongoing research - all in service of empowering everyone, everywhere to live better, longer every day.
Read the article featuring @geoffcook: bit.ly/3M9Wkge
Emily Passer retweeted
Noom launches a GLP-1-based, long-term, preventive health care program usatoday.com/story/shopping/…
Emily Passer retweeted
We've released $PGY 3Q25 #earnings.
Tune in to the call at 8:30 am ET, led by our CEO @galkrubiner, CFO Evangelos Perros, and President Sanjiv Das: investor.pagaya.com/news-rel…
Emily Passer retweeted
We've released $PGY 1Q25 #earnings. Tune in to the call at 8:30 am ET, led by our CEO @galkrubiner, CFO Evangelos Perros, and President Sanjiv Das:
investor.pagaya.com/news-rel…
Emily Passer retweeted
Join CEO @galkrubiner, CFO Evangelos Perros, and President Sanjiv Das tomorrow at 8:30 am ET for our 1Q25 #earnings call:
investor.pagaya.com/events/e…
$PGY
Emily Passer retweeted
.@Nasdaq Market Intelligence Desk @Cortland_Living @Pagayaltd join @JillMalandrino on @Nasdaq #TradeTalks to discuss how consumers and the housing market are responding to the macro environment. xitter.cf/i/broadcasts/1zqJVjnbW…
Emily Passer retweeted
Please join me tomorrow at 8:30 am ET for @Pagayaltd’s 4Q24 #earnings call. CFO Evangelos Perros, President Sanjiv Das, and I will be discussing our fourth-quarter results. $PGY
Join CEO @galkrubiner, CFO Evangelos Perros, and President Sanjiv Das tomorrow at 8:30 am ET for our 4Q24 #earnings call:
investor.pagaya.com/events/e…
$PGY
Emily Passer retweeted
scoop: CNN C.E.O. Mark Thompson tells me in a wide-ranging interview that CNN is launching a new streaming service. He also discussed how the network will cover Trump 2.0, the possibility of a “Trump Bump” and his relationship with his boss, David Zaslav.
nytimes.com/2025/01/23/busin…
